This finding is in contrast to results obtained in melanoma cells, in which centrinone-B was found to be less effective in cells with mutant TP53 (Denu et al. 2018), yet in line with p53-independent effects of CFI-400945 observed in lung cancer cells (Kawakami et al. 2018a). This evidence concerns the gene TP53 and lung carcinoma.